Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00079144 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL: NY-ESO-1 peptide vaccine
BIOLOGICAL: aldesleukin
BIOLOGICAL: filgrastim
BIOLOGICAL: incomplete Freund's adjuvant
BIOLOGICAL: therapeutic autologous lymphocytes
DRUG: cyclophosphamide
DRUG: fludarabine phosphate

Sponsor

National Cancer Institute (NCI)